Next Article in Journal
Dynamic Transcriptome Analysis Reveals Uncharacterized Complex Regulatory Pathway Underlying Dose IBA-Induced Embryogenic Redifferentiation in Cotton
Next Article in Special Issue
Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: an in Vitro and in Silico Study
Previous Article in Journal
Isolation of Four Lytic Phages Infecting Klebsiella pneumoniae K22 Clinical Isolates from Spain
Previous Article in Special Issue
The Retinoid and Non-Retinoid Ligands of the Rod Visual G Protein-Coupled Receptor
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 2
10.3390/ijms21020427
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach

by
Jing Zhang
,
Huajun Li
,
Yubo Zhang
,
Chaoran Zhao
,
Yizi Zhu
and
Mei Han
*
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(2), 427; https://doi.org/10.3390/ijms21020427
Submission received: 23 December 2019 / Revised: 5 January 2020 / Accepted: 7 January 2020 / Published: 9 January 2020
(This article belongs to the Special Issue Protein–Ligand Interactions: Deciphering the Molecular Targets and the Mechanisms of Action of Drugs and Natural Compounds)
Browse Figures
Versions Notes

Abstract

:
Stemazole exerts potent pharmacological effects against neurodegenerative diseases and protective effects in stem cells. However, on the basis of the current understanding, the molecular mechanisms underlying the effects of stemazole in the treatment of Alzheimer’s disease and Parkinson’s disease have not been fully elucidated. In this study, a network pharmacology-based strategy integrating target prediction, network construction, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, and molecular docking was adopted to predict the targets of stemazole relevant to the treatment of neurodegenerative diseases and to further explore the involved pharmacological mechanisms. The majority of the predicted targets were highly involved in the mitogen-activated protein kinase (MAPK) signaling pathway. RAC-alpha serine/threonine-protein kinase (AKT1), caspase-3 (CASP3), caspase-8 (CASP8), mitogen-activated protein kinase 8 (MAPK8), and mitogen-activated protein kinase 14 (MAPK14) are the core targets regulated by stemazole and play a central role in its anti-apoptosis effects. This work provides a scientific basis for further elucidating the mechanism underlying the effects of stemazole in the treatment of neurodegenerative diseases.

Graphical Abstract

1. Introduction

Neurodegenerative diseases, which comprise a type of chronic and progressive disease characterized by progressive degeneration of the structure and function of the nervous system [1], have become the most feared maladies in older people and one of the most serious healthcare problems worldwide [2]. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are two common neurodegenerative diseases that may lead to cognitive decline, memory loss, and movement disorders [3,4]. A total of 50 million people worldwide were living with AD as of 2018. This number will rise to approximately 152 million by 2050 [5]. According to the Global Burden of Disease Study, there are currently 6.2 million individuals suffering from PD, and the incidence of PD has surpassed that of AD [6].
Unfortunately, despite tremendous effort and expenditures, the existing clinical treatments for neurodegenerative diseases result in only temporary and limited symptomatic relief [7,8], and they are unable to treat the root causes or delay disease progression [9,10]. Therefore, there is an urgent need for effective therapeutic strategies based on the understanding of the pathological mechanisms underlying neurodegenerative diseases. Progressive neuronal damage or loss is one of the deterministic features of neurodegenerative diseases such as AD and PD [11,12]. Stem cell-based therapy has exciting potential for neuroprotection [13,14]. The loss of brain function caused by injury and aging can be treated by mobilizing the proliferation and differentiation of endogenous stem cells and replacing them with exogenous stem cells [15,16].
Recently, a novel small molecule with the ability to regulate stem cells has shown potential for the treatment of neurodegenerative diseases. Stemazole (ST) was discovered by a high-throughput screen [17]. We previously demonstrated that stemazole can prevent several types of stem cells from undergoing apoptosis under nutritional deprivation and injury conditions, including human hippocampal stem cells, pancreatic stem cells, cardiac stem cells [17], and human embryonic stem cells [18]. Our experimental evidence also revealed the neuroprotective effects of stemazole in animal models of neurodegenerative diseases. Stemazole exhibited a therapeutic effect in a beta-amyloid (Aβ) injection rat model of Alzheimer’s disease [19] and a protective effect on the impaired dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced acute mouse model of Parkinson’s disease [20]. In addition, stemazole has high absolute oral bioavailability, which makes it possible to develop it into an oral preparation. It can cross the blood–brain barrier and shows stable accumulation in the brain [21].
These studies have indicated that stemazole is a promising drug candidate. However, the regulatory mechanism underlying the effects of stemazole against AD and PD has not been systematically elucidated. Studies of the molecular targets and relevant signal pathways will provide a better understanding of the effects of stemazole in the treatment of neurodegenerative diseases.
Network pharmacology is an innovative method to study the mechanisms of drugs at the systemic level [22]. It encompasses bioinformatics, network analysis, and experimental approaches and integrates multiple sources of information [23]. Therefore, network approaches can accurately discriminate potential drug–target interactions [24].
Using the network pharmacology strategy, our study systematically investigated the potential targets and molecular mechanisms underlying the effects of stemazole against neurodegenerative diseases. First, we predicted the molecular targets of stemazole through chemical similarity analysis, pharmacophore model screening, and reverse docking. Pathological targets were identified using various bioinformatics platforms. We then performed enrichment analysis according to gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms and constructed a drug–target–pathway network. Finally, molecular docking was used to verify the interactions between stemazole and its targets.

2. Results

2.1. Screening of Potential Targets

A database of targets associated with neurodegenerative diseases and the targets of stemazole was constructed. A total of 1981 and 1063 targets associated with AD and PD, respectively, were identified using the DisGeNET database v6.0 (Table S1). A total of 559 predicted targets of stemazole were obtained from PharmMapper, Drug Repositioning and Adverse Reaction via Chemical-Protein Interactome (DRAR-CPI), Drug Positioning and Drug Repositioning via Chemical-Protein Interactome (DPDR-CPI), TargetNet, and ChemMapper after eliminating duplicates (Table S2). The intersection of the three lists identified 91 therapeutic targets of stemazole related to both AD and PD. To further identify the therapeutic targets involved in the regulation of stem cells, 91 targets in the DrugBank database, UniProt, the Human Protein Atlas, the Comparative Toxicogenomics Database, and KEGG were analyzed. Twenty-nine targets were found to be involved in the processes of apoptosis and were putative therapeutic targets of stemazole, mediating its effects against neurodegenerative diseases through an anti-apoptosis mechanism, as shown in Table 1.

2.2. Protein–Protein Interaction (PPI) Network Construction and Analysis

A total of 29 putative targets were uploaded to the STRING database to identify the functional partnerships and interactions between them. Protein interactions with a confidence score of 0.9 or higher were then imported into Cytoscape v3.7.1 to generate the protein–protein interaction (PPI) network, which comprised 23 nodes and 42 edges (Figure 1).
To identify the hub nodes and essential proteins in the PPI network, the topological parameters of the node degree were calculated by Network Analyzer, and the three centralities (betweenness, closeness, and subgraph) were determined by the CytoNCA plugin, as shown in Table 2. On the basis of the overlap between the top 10 proteins in each of the four groups, mitogen-activated protein kinase 8 (MAPK8), RAC-alpha serine/threonine-protein kinase (AKT1), MAPK14, tyrosine-protein kinase Fyn (FYN), caspase-3 (CASP3), estrogen receptor (ESR1), androgen receptor (AR), and CASP8 were identified as essential proteins with significant centrality values based on the network topology analysis.

2.3. GO and KEGG Pathway Enrichment Analyses

In addition, 29 potential targets were submitted to the g: Profiler server for KEGG pathway annotation and GO enrichment analysis. The KEGG pathways and gene ontology terms with a p-value ≤0.05 were significantly enriched. The top 20 components were graphed using the OmicShare cloud platform (Figure 2).
The KEGG pathway annotation showed that 27 of the 29 (93.1%) potential targets were significantly enriched in 53 pathways (Table S3). The statistical analysis indicated that 7 proteins were involved in the top 20 pathways (Figure 3) very frequently (≥10 times), which indicates that they are of great importance in the enriched pathways. The seven core proteins were MAPK8, AKT1, MAPK14, CASP3, CASP8, TNF, and CASP9. Among the enriched pathways, the MAPK signaling pathway was found to be dysregulated in neurodegenerative diseases. The predicted targets involved in the MAPK signaling pathway are shown in red in Figure 4.
The GO terms comprised three categories: biological process, molecular function, and cellular component. As shown in Figure 2, the top five biological processes included the regulation of cell death, regulation of apoptotic processes, regulation of programmed cell death, cell death, and apoptotic processes. The top five molecular functions included catalytic activity acting on a protein, identical protein binding, drug binding, protein kinase activity, and enzyme binding. The top five cellular components included membrane-bound organelles, membrane rafts, membrane microdomains, membrane regions, and intracellular organelles.

2.4. Molecular Docking

Docking studies were carried out between stemazole and five select important targets, AKT1, CASP3, CASP8, MAPK8, and MAPK14. These targets were chosen because not only were they key nodes of the PPI network, but they also played an important role in KEGG signaling pathways. According to the molecular docking results in Table 3, CASP3, MAPK14, AKT1, CASP8, and MAPK8 is the highest to the lowest order of affinities predicted for the interaction between each of the five protein targets and stemazole.
The docking results in this study demonstrate that the receptor–ligand interaction between ST and AKT1 involves both hydrophobic interactions and polar interactions. As shown in Figure 5A, their interaction is centered on a stable hydrophobic core consisting of several nonpolar residues in AKT1 (Ser205, Arg206, Ala212, Tyr263, Thr211, Trp80, Tyr272, Gln79, and Asp292). In addition, the hydroxyls within the main chains of Leu210 (3.10 Å) and His207 (3.06 Å) form two hydrogen bond contacts with the N17 atom of ST, which further stabilizes the entire interaction region. These interactions enable ST to bind to AKT1.
Moreover, the results in Figure 5B show that ST can bind to CASP3 by forming a hydrophobic interaction with the surrounding residues Asn208, Glu248, Phe250, Trp206, Ser249, and Phe247. ST could form three H-bonds with Glu246 (2.74 Å), Trp214 (3.13 Å), and Arg207 (2.93 Å).
The action modes of ST and CASP8 are shown in Figure 5C. ST binds to a pocket in CASP8, which is comprised of Phe468, Arg471, Leu440, Leu470, Lys472, Lys473, and Ile439. Two hydrogen bonds, STS23:Asp438OD2 (2.94 Å) and STS23:Leu474N (3.18 Å), further enhance the interaction between the ligand and the CASP8 protein.
According to the analysis shown in Figure 5D, ST was observed to form hydrophobic interactions with six residues in MAPK8 (Ala113, Asn114, Ile32, Leu110, Ala53, and Val40) and three hydrogen bonds (STN17:Gln117OE1 (3.33 Å), STN13:Asp112O (2.82 Å), and STN25:Met111N (2.73 Å)).
As shown in Figure 5E, ST was predicted to interact with MAPK14 via Val117, Gln120, Lys121, Leu217, and Leu122. ST also forms H-bonds with the residues Lys118 (2.84 Å) and Leu216 (2.95 Å).

3. Discussion

There is an urgent need to develop new treatment strategies because of the growing crisis resulting from neurodegenerative diseases and the poor efficacy of the existing approved drugs. Stemazole is a novel small molecule with neuroprotective effects, and its therapeutic efficacy in preclinical models of Alzheimer’s disease and Parkinson’s disease has been demonstrated in several studies. Stemazole also protects multiple types of stem cells from apoptosis. Here, a network pharmacology strategy was used to reveal the mechanism underlying the effects of stemazole. Therapeutic targets and the signaling pathways in which they participate were explored by reverse screening, PPI network construction, and pathway enrichment analysis. Information from various online servers and databases was integrated. The results we obtained are very reliable, as they benefitted from multiple information sources and different target identification methods. The specific interactions between stemazole and the targets were verified through molecular docking. Fifty-three signaling pathways and 29 proteins were shown to be involved. Five proteins were identified as the most probable targets. The results could provide a better understanding of the effects of stemazole on the treatment of neurodegenerative diseases and guide further studies of the development of stemazole as a stem cell drug.
We proposed that stemazole plays a therapeutic role in the treatment of neurodegenerative diseases that is mediated by an anti-apoptotic pathway, and the theoretical calculations were carried out on this basis. A similar therapeutic mechanism has been observed for other active small molecules. Pieper and colleagues discovered an aminopropyl carbazole named P7C3, which was utilized in an in vivo screen [25]. A series of P7C3-derived compounds showed neuroprotective activity in multiple models of Alzheimer’s disease [26], Parkinson’s disease [27], and traumatic brain injury [28] by protecting immature neurons from apoptotic cell death and promoting mature neuronal survival. Ye et al. reported a small molecule, 7,8-dihydroxyflavone (DHF), with the ability to protect neurons from apoptosis [29]. DHF has shown promising therapeutic efficacy in rodent models of Alzheimer’s disease [30], Parkinson’s disease [29], Huntington’s disease [31], and amyotrophic lateral sclerosis [32]. Previous experiments have proven that the anti-apoptosis mechanism may serve as the basis of a promising treatment. On the basis of this fact, it is crucial for drug research to explore the properties of drug candidates, especially their underlying molecular mechanisms. The mechanism underlying the effects of stemazole will be discussed in the following section.
The targets of stemazole were enriched in the MAPK signaling pathway, which was indicated by the KEGG pathway enrichment analysis. Previous studies have shown that the activation of the MAPK signaling pathway is highly correlated with the occurrence and development of neurodegenerative diseases. In the pathogenesis of AD, the MAPK pathway contributes to disease progression by inducing neuronal apoptosis, the transcription and activation of β- and γ-secretases, and the phosphorylation of Amyloid-beta precursor protein (APP) and tau. The role of the MAPK signaling pathway in PD involves the induction of neuronal death and neuroinflammatory responses associated with the levels of α-synuclein and functional deficiencies in parkin and Protein/nucleic acid deglycase DJ-1 [33]. The MAPK signaling pathway leads to apoptosis in both AD and PD, which suggests the importance of the anti-apoptosis ability of stemazole.
Two methods, centrality analysis of the PPI network and KEGG pathway analysis, were used individually to identify the core targets. According to the centrality and the node degree of the protein–protein interaction network, we identified the essential proteins, including MAPK8, AKT1, MAPK14, FYN, CASP3, ESR1, AR, and CASP8. Nodes with high centralities and node degrees often play the most important roles in the network. Among the top 20 enriched KEGG pathways, MAPK8, AKT1, MAPK14, CASP3, CASP8, TNF, and CASP9 were considered important because of their high frequency of involvement. The results of the two methods were not exactly the same. Proteins identified as central targets by both methods were selected for further analysis at the molecular level.
Five targets, MAPK8, AKT1, MAPK14, CASP3, and CASP8, were selected for the molecular docking studies. Stemazole showed good affinity towards the five targets, which validated the network pharmacology results. These targets play important roles in the pathophysiology of neurodegenerative diseases. Akt1 is highly expressed in the nervous system and is critical for the survival of neuronal cells [34]. Neuroprotective effects were observed after AKT1 kinase activity was enhanced, and pAKT1 was upregulated in cellular and animal models of neurodegenerative diseases [35]. JNK1 (MAPK8) is the main c-Jun N-terminal kinase involved in brain physiological activity [36]. Activated JNK plays an important role in amyloid plaque formation, Aβ deposition, the phosphorylation of tau, neuroinflammation, and Aβ-induced synaptic dysfunction [37], all of which are physiological processes involved in AD [38]. p38-α (MAPK14) mediates oxidative stress and leads to the aggregation of the tau protein [39]. After inhibiting p38 in rodent models of AD, the apoptosis of nerve cells and damage to cognitive function were greatly reduced [40]. In addition, p38 can also lead to the degeneration and death of dopaminergic neurons in Parkinson’s disease [41]. Caspase-8 and caspase-3 are two cysteine aspartate-specific proteases. Apoptotic neurons act as part of initiator and executioner cascades in apoptotic cascades [42]. The experimental results indicated that caspase-8 can mediate neuronal death induced by beta-amyloid protein [43]. As a downstream effector of caspase-8, caspase-3 is the core executioner caspase. Activation and increased expression of caspase-3 were observed in the brain in AD. Caspase-3 is also involved in APP proteolysis and Aβ peptide formation [44]. Through genetic intervention via caspase-3, dopaminergic neurons can be protected against cell death induced by oxidative stress, which suggests that caspase-3 is an important target for the prevention of the progression of PD [45].
The results of the network analysis provide a theoretical basis and important information that could be useful for elucidating the mechanisms underlying the therapeutic effects of stemazole and identifying potential targets, but the experimental verification of the targets and specific interactions will be necessary in the future.

4. Materials and Methods

The experimental flow is shown in Figure 6.

4.1. Identification of Pathological Targets

Targets associated with AD and PD were identified using the DisGeNET database v6.0 (http://www.disgenet.org/) [46]. Apoptosis-related proteins and genes were identified using the Human Protein Atlas (https://www.proteinatlas.org/) [47], the DrugBank database (https://www.drugbank.ca/) [48], UniProt (https://www.uniprot.org/) [49], the Comparative Toxicogenomics Database (CTD, http://ctdbase.org/) [50], and the Kyoto Encyclopedia of Genes and Genomes (KEGG, https://www.kegg.jp/) [51].

4.2. Virtual Screening of Drug Targets

The three-dimensional structure of stemazole was built and optimized in Gaussian 09W software [52] at the DFT-B3LYP/6-311G (d, p) level. The optimized structure was saved in mol2 and sdf format prior to the screening processes. The SMILES string of stemazole was generated using Advanced Chemistry Development/ChemSketch software [53].
According their theoretical basis, reverse screening methods are classified into one of three types: shape screening, pharmacophore screening, or reverse docking [54]. Each method has its own characteristics in terms of algorithms and programs. Each database contains only a small number of protein targets. Therefore, several servers were used to combine prediction methods to utilize a wide range of targets and obtain reliable results.
The 3D structural file or SMILES string was submitted to the PharmMapper (http://lilab-ecust.cn/pharmmapper/) [55], DRAR-CPI (http://cpi.bio-x.cn/drar/) [56], DPDR-CPI (http://cpi.bio-x.cn/dpdr/) [57], TargetNet (http://targetnet.scbdd.com/) [58], and ChemMapper (http://lilab-ecust.cn/chemmapper/) [59] servers to predict the targets of stemazole. Homo sapiens was chosen as the organism.
After adding the targets together and deleting the duplicates, the obtained predicted targets were assumed to be pathological targets. Then, the therapeutic targets of stemazole relevant to its effects on AD and PD via its anti-apoptosis mechanism were preliminarily determined.

4.3. PPI Network Construction and Analysis

The identified targets were uploaded to the STRING database v11.0 (http://string-db.org) [60] to obtain the protein–protein interaction information, including the physical and functional associations. Protein interactions with a confidence score of 0.9 or higher were exported in TSV format. The PPI network was visualized by Cytoscape v3.7.1 [61]. Network Analyzer [62] was utilized for calculating the network topology parameters, in which the network was treated as undirected. The CytoNCA plugin (v2.1.6) [63] was used to measure the topology scores of the nodes, including the betweenness, closeness, and subgraph centrality. The option “without weight” was selected.

4.4. GO and KEGG Pathway Enrichment Analyses

The gene ontology and KEGG pathway enrichment analyses were carried out using the web server g: Profiler (https://biit.cs.ut.ee/gprofiler) [64] and visualized by the OmicShare cloud platform as a bubble chart (http://www.omicshare.com/). The target-pathway network was constructed in Cytoscape v3.7.1.

4.5. Molecular Docking

The X-ray crystal structures of the targets (http://www.rcsb.org/) [65,66], including AKT1 (PDB ID: 6HHF), CASP3 (PDB ID: 5IAG), CASP8 (PDB ID: 3KJN), MAPK8 (PDB ID: 3O2M), and MAPK14 (PDB ID: 5ETC), were obtained from the Protein Data Bank (PDB). The water molecules and hetero atoms were then removed from the proteins using Chimera 1.13.1 [67]. The protein receptor files and ligand file were processed using AutoDock Tools 1.5.6, including adding hydrogen atoms, calculating and adding Gasteiger charges, merging nonpolar hydrogen atoms, and setting rotatable torsion bonds. Then, they were converted to pdbqt format. The parameters of the grid box are shown in Table 4. Each grid box was centered on and encompassed the entirety of the active site. Molecular docking between stemazole and the core targets was carried out using AutoDock 4.2 software [68] with the Lamarckian genetic algorithm. The number of GA runs was set to 50, and other parameters were set to default values. The binding mode with the lowest binding energy in the cluster with the most conformations was selected for further analysis. The interactions between stemazole and the predicted targets were visualized and displayed as 3D diagrams and 2D diagrams by using PyMOL 1.8 and ligplus.

5. Conclusions

The potential targets and molecular mechanisms underlying the effects of stemazole against AD and PD mediated by anti-apoptosis were systematically investigated by network pharmacology. The key pathway involved in the neuroprotective effects of stemazole is the MAPK signaling pathway, and five key targets were identified, including MAPK8, AKT1, MAPK14, CASP3, and CASP8. In summary, the presented findings may inspire and guide further pharmacological studies of the effects of stemazole against neurodegenerative diseases.

Supplementary Materials

Supplementary materials can be found at https://www.mdpi.com/1422-0067/21/2/427/s1. Table S1: Targets associated with Alzheimer’s disease and Parkinson’s disease, Table S2: Predicted targets of stemazole, Table S3: The results of the GO and KEGG pathway enrichment.

Author Contributions

Conceptualization, M.H. and J.Z.; methodology, J.Z.; investigation, J.Z., H.L., and Y.Z. (Yizi Zhu); writing—original draft preparation, J.Z.; writing—review and editing, M.H., H.L., and Y.Z. (Yubo Zhang); visualization, C.Z. and Y.Z. (Yizi Zhu); funding acquisition, M.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China, grant number 81173139 and 30672491, and the National Key Research and Development Program of China, grant number 2017YFC0113305.

Acknowledgments

The authors would like to thank Hongwei Jin from the School of Pharmaceutical Sciences at Peking University for helpful advice. The authors would also like to thank Ying Liu for help with the molecular docking studies.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

GOgene ontology
KEGGKyoto Encyclopedia of Genes and Genomes
AKT1RAC-alpha serine/threonine-protein kinase
CASP3caspase-3
CASP8caspase-8
MAPK8mitogen-activated protein kinase 8
MAPK14mitogen-activated protein kinase 14
ADAlzheimer’s disease
PDParkinson’s disease
STStemazole
Aβbeta-amyloid
MPTP1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
ABL1Tyrosine-protein kinase ABL1
ACHEAcetylcholinesterase
ARAndrogen receptor
CASP9Caspase-9
CDK5Cyclin-dependent-like kinase 5
CSF1RMacrophage colony-stimulating factor 1 receptor
DAPK1Death-associated protein kinase 1
DRD3D(3) dopamine receptor
ESR1Estrogen receptor
FGF2Fibroblast growth factor 2
FYNTyrosine-protein kinase Fyn
GAPDHGlyceraldehyde-3-phosphate dehydrogenase
HGFHepatocyte growth factor
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductase
IGF1RInsulin-like growth factor 1 receptor
INSRInsulin receptor
MAPK8IP1C-Jun-amino-terminal kinase-interacting protein 1
MMP9Matrix metalloproteinase-9
PIK3CGPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
PPARDPeroxisome proliferator-activated receptor delta
PPARGPeroxisome proliferator-activated receptor gamma
PPIFPeptidyl-prolyl cis-trans isomerase F, mitochondrial
PTGS2Prostaglandin G/H synthase 2
TNFTumor necrosis factor
PPIProtein–protein interaction
DHF7,8-dihydroxyflavone

References

  1. Friedlander, R.M. Mechanisms of disease: Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003, 348, 1365–1375. [Google Scholar] [CrossRef] [PubMed]
  2. Wyss-Coray, T. Ageing, neurodegeneration and brain rejuvenation. Nature 2016, 539, 180–186. [Google Scholar] [CrossRef] [PubMed]
  3. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7, 137–152. [Google Scholar] [CrossRef] [PubMed]
  4. Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet 2015, 386, 896–912. [Google Scholar] [CrossRef]
  5. Patterson, C. The State of the Art of Dementia Research: New Frontiers; World Alzheimer Report 2018; Alzheimer’s Disease International (ADI): London, UK, 2018. [Google Scholar]
  6. Dorsey, E.R.; Bloem, B.R. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018, 75, 9–10. [Google Scholar] [CrossRef]
  7. Bachurin, S.O.; Bovina, E.V.; Ustyugov, A.A. Drugs in Clinical Trials for Alzheimer’s Disease: The Major Trends. Med. Res. Rev. 2017, 37, 1186–1225. [Google Scholar] [CrossRef]
  8. Fernandez, H.H. 2015 Update on Parkinson disease. Clevel. Clin. J. Med. 2015, 82, 563–568. [Google Scholar] [CrossRef]
  9. Cummings, J.; Aisen, P.S.; DuBois, B.; Frölich, L.; Jack, C.R.; Jones, R.W.; Morris, J.C.; Raskin, J.; Dowsett, S.A.; Scheltens, P. Drug development in Alzheimer’s disease: The path to 2025. Alzheimer’s Res. Ther. 2016, 8, 39. [Google Scholar] [CrossRef] [Green Version]
  10. Charvin, D.; Medori, R.; Hauser, R.A.; Rascol, O. Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat. Rev. Drug Discov. 2018, 17, 804–822. [Google Scholar] [CrossRef]
  11. Palop, J.J.; Chin, J.; Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006, 443, 768–773. [Google Scholar] [CrossRef]
  12. Lev, N.; Melamed, E.; Offen, D. Apoptosis and Parkinson’s disease. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2003, 27, 245–250. [Google Scholar] [CrossRef]
  13. Singh, S.; Srivastava, A.; Srivastava, P.; Dhuriya, Y.K.; Pandey, A.; Kumar, D.; Rajpurohit, C.S. Advances in Stem Cell Research—A Ray of Hope in Better Diagnosis and Prognosis in Neurodegenerative Diseases. Front. Mol. Biosci. 2016, 3, 72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Stoddard-Bennett, T.; Pera, R.R. Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells 2019, 8, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Yue, C.; Jing, N. The promise of stem cells in the therapy of Alzheimer’s disease. Transl. Neurodegener. 2015, 4, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Han, F.; Baremberg, D.; Gao, J.; Duan, J.; Lu, X.; Zhang, N.; Chen, Q. Development of stem cell-based therapy for Parkinson’s disease. Transl. Neurodegener. 2015, 4, 16. [Google Scholar] [CrossRef] [Green Version]
  17. Sun, Y.; Wang, W.; Sun, Y.; Han, M. Synthesis and biological evaluation of a novel human stem/progenitor cells proliferation activator: 4-(4-(5-mercapto-1,3,4-oxadiazol-2-yl)phenyl) thiosemicarbazide (Stemazole). Eur. J. Med. Chem. 2011, 46, 2930–2936. [Google Scholar] [CrossRef]
  18. Sun, Y.; Zhang, X.; Li, H.; Xu, S.; Zhang, X.; Liu, Y.; Han, M.; Wen, J. Stemazole promotes survival and preserves stemness in human embryonic stem cells. FEBS J. 2018, 285, 531–541. [Google Scholar] [CrossRef]
  19. Han, M.; Liu, Y.; Tan, Q.; Zhang, B.; Wang, W.; Liu, J.; Zhang, X.-J.; Wang, Y.-Y.; Zhang, J.-M. Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer’s disease. Eur. J. Pharmacol. 2011, 657, 104–110. [Google Scholar] [CrossRef]
  20. Guo, Z.; Xu, S.; Du, N.; Liu, J.; Huang, Y.; Han, M. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson’s disease: Involvement of the dopamine system. Neurosci. Lett. 2016, 616, 152–159. [Google Scholar] [CrossRef] [Green Version]
  21. Li, H.; Tan, Q.; Zhang, Y.; Zhang, J.; Zhao, C.; Lu, S.; Qiao, J.; Han, M. Pharmacokinetics and absolute oral bioavailability of stemazole by UPLC-MS/MS and its bio-distribution through tritium labeling. Drug Test. Anal. 2019. [Google Scholar] [CrossRef]
  22. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4, 682–690. [Google Scholar] [CrossRef]
  23. Park, M.; Park, S.-Y.; Lee, H.-J.; Kim, C.-E. A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach. Molecules 2018, 23, 2841. [Google Scholar] [CrossRef] [Green Version]
  24. Boezio, B.; Audouze, K.; Ducrot, P.; Taboureau, O. Network-based Approaches in Pharmacology. Mol. Inform. 2017, 36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Pieper, A.A.; Xie, S.; Capota, E.; Estill, S.J.; Zhong, J.; Long, J.M.; Becker, G.L.; Huntington, P.; Goldman, S.E.; Shen, C.-H.; et al. Discovery of a Proneurogenic, Neuroprotective Chemical. Cell 2010, 142, 39–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Voorhees, J.R.; Remy, M.T.; Cintron-Perez, C.J.; El Rassi, E.; Khan, M.Z.; Dutca, L.M.; Yin, T.C.; McDaniel, L.N.; Williams, N.S.; Brat, D.J.; et al. (-)-P7C3-S243 Protects a Rat Model of Alzheimer’s Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia. Biol. Psychiatry 2018, 84, 488–498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. De Jesus-Cortes, H.; Xu, P.; Drawbridge, J.; Estill, S.J.; Huntington, P.; Tran, S.; Britt, J.; Tesla, R.; Morlock, L.; Naidoo, J.; et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc. Natl. Acad. Sci. USA 2012, 109, 17010–17015. [Google Scholar] [CrossRef] [Green Version]
  28. Yin, T.C.; Britt, J.K.; De Jesus-Cortes, H.; Lu, Y.; Genova, R.M.; Khan, M.Z.; Voorhees, J.R.; Shao, J.; Katzman, A.C.; Huntington, P.J.; et al. P7C3 Neuroprotective Chemicals Block Axonal Degeneration and Preserve Function after Traumatic Brain Injury. Cell Rep. 2014, 8, 1731–1740. [Google Scholar] [CrossRef] [Green Version]
  29. Jang, S.-W.; Liu, X.; Yepes, M.; Shepherd, K.R.; Miller, G.W.; Liu, Y.; Wilson, W.D.; Xiao, G.; Blanchi, B.; Sun, Y.E.; et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. USA 2010, 107, 2687–2692. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Zhang, Z.; Liu, X.; Schroeder, J.P.; Chan, C.-B.; Song, M.; Yu, S.P.; Weinshenker, D.; Ye, K. 7,8-Dihydroxyflavone Prevents Synaptic Loss and Memory Deficits in a Mouse Model of Alzheimer’s Disease. Neuropsychopharmacology 2014, 39, 638–650. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Jiang, M.; Peng, Q.; Liu, X.; Jin, J.; Hou, Z.; Zhang, J.; Mori, S.; Ross, C.A.; Ye, K.; Duan, W. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntingtons disease. Hum. Mol. Genet. 2013, 22, 2462–2470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Korkmaz, O.T.; Aytan, N.; Carreras, I.; Choi, J.-K.; Kowall, N.W.; Jenkins, B.G.; Dedeoglu, A. 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 2014, 566, 286–291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Kim, E.K.; Choi, E.-J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2010, 1802, 396–405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Griffin, R.J.; Moloney, A.; Kelliher, M.; Johnston, J.A.; Ravid, R.; Dockery, P.; O’Connor, R.; O’Neill, C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J. Neurochem. 2005, 93, 105–117. [Google Scholar] [CrossRef] [PubMed]
  35. Ahmad, F.; Nidadavolu, P.; Durgadoss, L.; Ravindranath, V. Critical cysteines in Akt1 regulate its activity and proteasomal degradation: Implications for neurodegenerative diseases. Free Radic. Biol. Med. 2014, 74, 118–128. [Google Scholar] [CrossRef]
  36. Coffey, E.T.; Smiciene, G.; Hongisto, V.; Cao, J.; Brecht, S.; Herdegen, T.; Courtney, M.J. c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci. 2002, 22, 4335–4345. [Google Scholar] [CrossRef]
  37. Zhou, Q.; Wang, M.; Du, Y.; Zhang, W.; Bai, M.; Zhang, Z.; Li, Z.; Miao, J. Inhibition of c-Jun N-Terminal Kinase Activation Reverses Alzheimer Disease Phenotypes in APPswe/PS1dE9 Mice. Ann. Neurol. 2015, 77, 637–654. [Google Scholar] [CrossRef]
  38. Mehan, S.; Meena, H.; Sharma, D.; Sankhla, R. JNK: A Stress-Activated Protein Kinase Therapeutic Strategies and Involvement in Alzheimer’s and Various Neurodegenerative Abnormalities. J. Mol. Neurosci. 2011, 43, 376–390. [Google Scholar] [CrossRef]
  39. Giraldo, E.; Lloret, A.; Fuchsberger, T.; Viña, J. Aβ and tau toxicities in Alzheimer’s are linked via oxidative stress-induced p38 activation: Protective role of vitamin E. Redox Biol. 2014, 2, 873–877. [Google Scholar] [CrossRef] [Green Version]
  40. Guo, J.; Cheng, J.; North, B.J.; Wei, W. Functional analyses of major cancer-related signaling pathways in Alzheimer’s disease etiology. Biochim. Biophys. Acta. Rev. Cancer 2017, 1868, 341–358. [Google Scholar] [CrossRef]
  41. Corti, O.; Hampe, C.; Koutnikova, H.; Darios, F.; Jacquier, S.; Prigent, A.; Robinson, J.C.; Pradier, L.; Ruberg, M.; Mirande, M.; et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: Linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 2003, 12, 1427–1437. [Google Scholar] [CrossRef] [Green Version]
  42. Louneva, N.; Cohen, J.W.; Han, L.Y.; Talbot, K.; Wilson, R.S.; Bennett, D.A.; Trojanowski, J.Q.; Arnold, S.E. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer’s disease. Am. J. Pathol. 2008, 173, 1488–1495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Ivins, K.J.; Thornton, P.L.; Rohn, T.T.; Cotman, C.W. Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8. Neurobiol. Dis. 1999, 6, 440–449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. D’Amelio, M.; Cavallucci, V.; Middei, S.; Marchetti, C.; Pacioni, S.; Ferri, A.; Diamantini, A.; De Zio, D.; Carrara, P.; Battistini, L.; et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer’s disease. Nat. Neurosci. 2011, 14, 69–76. [Google Scholar] [CrossRef] [Green Version]
  45. Kim, J.S.; Ha, J.Y.; Yang, S.J.; Son, J.H. A Novel Non-Apoptotic Role of Procaspase-3 in the Regulation of Mitochondrial Biogenesis Activators. J. Cell. Biochem. 2018, 119, 347–357. [Google Scholar] [CrossRef] [PubMed]
  46. Pinero, J.; Bravo, A.; Queralt-Rosinach, N.; Gutierrez-Sacristan, A.; Deu-Pons, J.; Centeno, E.; Garcia-Garcia, J.; Sanz, F.; Furlong, L.I. DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017, 45, D833–D839. [Google Scholar] [CrossRef]
  47. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 2010, 28, 1248–1250. [Google Scholar] [CrossRef]
  48. Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018, 46, D1074–D1082. [Google Scholar] [CrossRef]
  49. Bateman, A.; Martin, M.-J.; Orchard, S.; Magrane, M.; Alpi, E.; Bely, B.; Bingley, M.; Britto, R.; Bursteinas, B.; Busiello, G.; et al. UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res. 2019, 47, D506–D515. [Google Scholar] [CrossRef] [Green Version]
  50. Davis, A.P.; Grondin, C.J.; Johnson, R.J.; Sciaky, D.; McMorran, R.; Wiegers, J.; Wiegers, T.C.; Mattingly, C.J. The Comparative Toxicogenomics Database: Update 2019. Nucleic Acids Res. 2019, 47, D948–D954. [Google Scholar] [CrossRef] [PubMed]
  51. Kanehisa, M.; Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000, 28, 27–30. [Google Scholar] [CrossRef]
  52. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. Gaussian 09 Revision A.1; Gaussian, Inc.: Wallingford, CT, USA, 2009. [Google Scholar]
  53. ACD/Labs. ACD/ChemSketch, Version 2018.2; Advanced Chemistry Development, Inc.: Toronto, ON, Canada, 2019. [Google Scholar]
  54. Huang, H.; Zhang, G.; Zhou, Y.; Lin, C.; Chen, S.; Lin, Y.; Mai, S.; Huang, Z. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds. Front. Chem. 2018, 6, 138. [Google Scholar] [CrossRef] [PubMed]
  55. Wang, X.; Shen, Y.; Wang, S.; Li, S.; Zhang, W.; Liu, X.; Lai, L.; Pei, J.; Li, H. PharmMapper 2017 update: A web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017, 45, W356–W360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Luo, H.; Chen, J.; Shi, L.; Mikailov, M.; Zhu, H.; Wang, K.; He, L.; Yang, L. DRAR-CPI: A server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011, 39, W492–W498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Luo, H.; Zhang, P.; Cao, X.H.; Du, D.; Ye, H.; Huang, H.; Li, C.; Qin, S.; Wan, C.; Shi, L.; et al. DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome. Sci. Rep. 2016, 6, 35996. [Google Scholar] [CrossRef] [Green Version]
  58. Yao, Z.-J.; Dong, J.; Che, Y.-J.; Zhu, M.-F.; Wen, M.; Wang, N.-N.; Wang, S.; Lu, A.-P.; Cao, D.-S. TargetNet: A web service for predicting potential drug-target interaction profiling via multi-target SAR models. J. Comput. Aided Mol. Des. 2016, 30, 413–424. [Google Scholar] [CrossRef]
  59. Gong, J.; Cai, C.; Liu, X.; Ku, X.; Jiang, H.; Gao, D.; Li, H. ChemMapper: A versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Bioinformatics 2013, 29, 1827–1829. [Google Scholar] [CrossRef] [Green Version]
  60. Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K.P.; et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015, 43, D447–D452. [Google Scholar] [CrossRef]
  61. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef]
  62. Assenov, Y.; Ramirez, F.; Schelhorn, S.-E.; Lengauer, T.; Albrecht, M. Computing topological parameters of biological networks. Bioinformatics 2008, 24, 282–284. [Google Scholar] [CrossRef] [Green Version]
  63. Tang, Y.; Li, M.; Wang, J.; Pan, Y.; Wu, F.-X. CytoNCA: A cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems 2015, 127, 67–72. [Google Scholar] [CrossRef]
  64. Raudvere, U.; Kolberg, L.; Kuzmin, I.; Arak, T.; Adler, P.; Peterson, H.; Vilo, J. g:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019, 47, W191–W198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Burley, S.K.; Berman, H.M.; Bhikadiya, C.; Bi, C.; Chen, L.; Di Costanzo, L.; Christie, C.; Dalenberg, K.; Duarte, J.M.; Dutta, S.; et al. RCSB Protein Data Bank: Biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Res. 2018, 47, D464–D474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 21 00427 g001 550
Figure 1. Protein–protein interaction network. The size of the circle represents the node degree of the target protein. MAPK, mitogen-activated protein kinase; AKT1, RAC-alpha serine/threonine-protein kinase; FYN, tyrosine-protein kinase Fyn; CASP, caspase; ESR, estrogen receptor; AR, androgen receptor; TNF, tumor necrosis factor; ABL1, tyrosine-protein kinase ABL1; CDK, Cyclin-dependent-like kinase; IGF1R, insulin-like growth factor 1 receptor; INSR, insulin receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HGF, hepatocyte growth factor; PIK3CG, hosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; PPARG, peroxisome proliferator-activated receptor gamma; DAPK, death-associated protein kinase; MMP, matrix metalloproteinase; PTG, prostaglandin G/H synthase; FGF, fibroblast growth factor.
Figure 1. Protein–protein interaction network. The size of the circle represents the node degree of the target protein. MAPK, mitogen-activated protein kinase; AKT1, RAC-alpha serine/threonine-protein kinase; FYN, tyrosine-protein kinase Fyn; CASP, caspase; ESR, estrogen receptor; AR, androgen receptor; TNF, tumor necrosis factor; ABL1, tyrosine-protein kinase ABL1; CDK, Cyclin-dependent-like kinase; IGF1R, insulin-like growth factor 1 receptor; INSR, insulin receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HGF, hepatocyte growth factor; PIK3CG, hosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; PPARG, peroxisome proliferator-activated receptor gamma; DAPK, death-associated protein kinase; MMP, matrix metalloproteinase; PTG, prostaglandin G/H synthase; FGF, fibroblast growth factor.
Ijms 21 00427 g001
Ijms 21 00427 g002 550
Figure 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and gene ontology enrichment analyses of 29 target proteins (p-value ≤ 0.05). (A) The top 20 KEGG pathways. (B) The top 20 biological processes. (C) The top 20 molecular functions. (D) Eleven cellular components. The color scales indicate the different thresholds for the p-values, and the sizes of the dots represent the number of genes corresponding to each term.
Figure 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and gene ontology enrichment analyses of 29 target proteins (p-value ≤ 0.05). (A) The top 20 KEGG pathways. (B) The top 20 biological processes. (C) The top 20 molecular functions. (D) Eleven cellular components. The color scales indicate the different thresholds for the p-values, and the sizes of the dots represent the number of genes corresponding to each term.
Ijms 21 00427 g002
Ijms 21 00427 g003 550
Figure 3. Target-pathway network. The V-shaped patterns represent pathways, and the circles represent targets. The sizes of the circles represent the degree of importance in the pathway. IL, Interleukin.
Figure 3. Target-pathway network. The V-shaped patterns represent pathways, and the circles represent targets. The sizes of the circles represent the degree of importance in the pathway. IL, Interleukin.
Ijms 21 00427 g003
Ijms 21 00427 g004 550
Figure 4. Representation of the targets of stemazole (ST) involved in the MAPK signaling pathway. The pathway maps were constructed using the KEGG mapper. The green rectangles and red rectangles represent unidentified proteins and identified proteins, respectively.
Figure 4. Representation of the targets of stemazole (ST) involved in the MAPK signaling pathway. The pathway maps were constructed using the KEGG mapper. The green rectangles and red rectangles represent unidentified proteins and identified proteins, respectively.
Ijms 21 00427 g004
Ijms 21 00427 g005 550
Figure 5. Molecular models of the binding of stemazole to the predicted targets (A) AKT1, (B) CASP3, (C) CASP8, (D) MAPK8, and (E) MAPK14 shown as 3D diagrams and 2D diagrams.
Figure 5. Molecular models of the binding of stemazole to the predicted targets (A) AKT1, (B) CASP3, (C) CASP8, (D) MAPK8, and (E) MAPK14 shown as 3D diagrams and 2D diagrams.
Ijms 21 00427 g005
Ijms 21 00427 g006 550
Figure 6. The experimental flow of this study. AD, Alzheimer’s disease; PD, Parkinson’s disease; PPI, protein–protein interaction; GO, gene ontology.
Figure 6. The experimental flow of this study. AD, Alzheimer’s disease; PD, Parkinson’s disease; PPI, protein–protein interaction; GO, gene ontology.
Ijms 21 00427 g006
Table
Table 1. Putative therapeutic targets of stemazole mediating its effects against neurodegenerative diseases.
Table 1. Putative therapeutic targets of stemazole mediating its effects against neurodegenerative diseases.
No.SymbolProtein NameDatabase
1ABL1Tyrosine-protein kinase ABL1DRAR-CPI, DPDR-CPI, PharmMapper
2ACHEAcetylcholinesteraseChemMapper
3AKT1RAC-alpha serine/threonine-protein kinaseChemMapper
4ARAndrogen receptorDPDR-CPI, ChemMapper
5CASP3Caspase-3PharmMapper
6CASP8Caspase-8DPDR-CPI
7CASP9Caspase-9TargetNet
8CDK5Cyclin-dependent-like kinase 5ChemMapper
9CSF1RMacrophage colony-stimulating factor 1 receptorDPDR-CPI
10DAPK1Death-associated protein kinase 1PharmMapper
11DRD3D(3) dopamine receptorChemMapper
12ESR1Estrogen receptorDRAR-CPI, PharmMapper, ChemMapper, TargetNet
13FGF2Fibroblast growth factor 2ChemMapper
14FYNTyrosine-protein kinase FynDPDR-CPI
15GAPDHGlyceraldehyde-3-phosphate dehydrogenaseChemMapper
16HGFHepatocyte growth factorChemMapper
17HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductasePharmMapper
18IGF1RInsulin-like growth factor 1 receptorDRAR-CPI
19INSRInsulin receptorPharmMapper
20MAPK14Mitogen-activated protein kinase 14PharmMapper, ChemMapper
21MAPK8Mitogen-activated protein kinase 8DPDR-CPI, PharmMapper, ChemMapper
22MAPK8IP1C-Jun-amino-terminal kinase-interacting protein 1ChemMapper
23MMP9Matrix metalloproteinase-9DPDR-CPI
24PIK3CGPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformDPDR-CPI, TargetNet
25PPARDPeroxisome proliferator-activated receptor deltaDRAR-CPI
26PPARGPeroxisome proliferator-activated receptor gammaDRAR-CPI, ChemMapper
27PPIFPeptidyl-prolyl cis-trans isomerase F, mitochondrialChemMapper
28PTGS2Prostaglandin G/H synthase 2ChemMapper, TargetNet
29TNFTumor necrosis factorDRAR-CPI
Table
Table 2. Topological parameters of the targets.
Table 2. Topological parameters of the targets.
DegreeSubgraghBetweennessCloseness
MAPK8935.681553164.866670.6111111
AKT1933.1379871.30.5945946
MAPK14840.777042100.9333340.52380955
FYN623.114271116.722220.5
CASP3620.88825263.60.5
ESR1516.39299446.5666660.5
AR415.24064353.4333340.47826087
CASP849.14898311.60.4680851
ABL1414.081305180.41509435
TNF613.0893478.8666670.4489796
CASP937.8370923.44444440.43137255
CDK535.5267058.50.37931034
INSR23.5084944420.4
IGF1R22.985051400.4
PPARG22.977374800.3859649
HGF23.248006380.36666667
GAPDH24.9902515.83333350.36065573
PIK3CG25.32327132.33333330.33846155
PTGS211.957166800.3859649
DAPK112.139050500.33846155
MMP911.95716700.33846155
FGF211.614988400.33846155
MAPK8IP112.566433700.28947368
Table
Table 3. Results of molecular docking between stemazole (ST) and the predicted target.
Table 3. Results of molecular docking between stemazole (ST) and the predicted target.
ReceptorsBinding Energy (ΔG)/kcal·moL−1Inhibit Constant (Ki)/μM
CASP3−7.453.45
MAPK14−7.215.17
AKT1−7.046.86
CASP8−6.4817.92
MAPK8−6.3820.9
Table
Table 4. Parameters of the grid box in molecular docking.
Table 4. Parameters of the grid box in molecular docking.
TargetsPDB IDGrid CenterNptsSpacing
AKT16HHF5.2302.27720.62060 60 600.375
CASP35IAG8.173−18.986−21.03260 60 600.375
CASP83KJN−5.71317.72116.59760 60 600.375
MAPK83O2M17.929107.60553.79760 60 600.375
MAPK145ETC5.88176.86222.00260 60 600.375

Share and Cite

MDPI and ACS Style

Zhang, J.; Li, H.; Zhang, Y.; Zhao, C.; Zhu, Y.; Han, M. Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach. Int. J. Mol. Sci. 2020, 21, 427. https://doi.org/10.3390/ijms21020427

AMA Style

Zhang J, Li H, Zhang Y, Zhao C, Zhu Y, Han M. Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach. International Journal of Molecular Sciences. 2020; 21(2):427. https://doi.org/10.3390/ijms21020427

Chicago/Turabian Style

Zhang, Jing, Huajun Li, Yubo Zhang, Chaoran Zhao, Yizi Zhu, and Mei Han. 2020. "Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach" International Journal of Molecular Sciences 21, no. 2: 427. https://doi.org/10.3390/ijms21020427

APA Style

Zhang, J., Li, H., Zhang, Y., Zhao, C., Zhu, Y., & Han, M. (2020). Uncovering the Pharmacological Mechanism of Stemazole in the Treatment of Neurodegenerative Diseases Based on a Network Pharmacology Approach. International Journal of Molecular Sciences, 21(2), 427. https://doi.org/10.3390/ijms21020427

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop